吡格列酮与厄贝沙坦联合在早期2型糖尿病肾病治疗中的临床应用分析

目的探讨吡格列酮与厄贝沙坦联合治疗早期2型糖尿病肾病的临床疗效。方法选取2010年6月～2011年6月某院收治的糖尿病肾病患者90例,按随机数字表法分为观察组和对照组。对照组给予吡格列酮,观察组在对照组基础上加用厄贝沙坦。3个月后观察两组临床疗效、血糖及肾功能指标变化。结果观察组总有效率为89.9%(40/45),对照组为66.7%(30/45),差异有统计学意义(P﹤0.05);治疗后两组血糖指标[HbA1C、FPG、PBG2h]及肾功能指标[SCr、BUN、UAER、mAlb]水平均显著下降(P﹤0.05),观察组较对照组下降更为显著(P﹤0.05);两组用药前后肝肾功能未见明显异常,均未出现明显不良反应。结论吡格列酮与厄贝沙坦联合治疗早期2型糖尿病肾病能起到协同作用,显著提高疗效,降低血糖,改善肾功能,值得临床推广和探讨。

Analysis of the clinical application of Pioglitazone combined with irbesartan in treatment of early diabetic nephropathy in type 2 diabetes mellitus

OBJECTIVE To pioglitazone combined with irbesartan in treatment of early diabetic nephropathy in type 2 diabetes mellitus clinical curative effect.METHODS From June 2010 2011 June 90 cases with diabetic nephropathy in our hospital were selected,and were randomly divided into observation group and control group.The control group was given pioglitazone,and observation group was given pioglitazone and irbesartan.After 3 months,we observed the clinical efficacy,blood glucose and renal function indexes of the two studies.RESULTS In the study group,the total effective rate was 89.9%(40/45),the control group was 66.7%(30/45),there was significant difference in the two groups(P﹤0.05).After the treatment,blood glucose index[HbA1C,FPG,PBG2h]and renal function index[SCr,BUN,UAER,mAlb]significantly decreased(P﹤0.05),the observation greatly decreased group compared with the control group(P﹤0.05);When compared two groups before and after treatment,liver and kidney functions showed no significant difference,there was no obvious adverse reaction.CONCLUSION Pioglitazone combined with irbesartan in treatment of early diabetic nephropathy in type 2 diabetes mellitus can play a synergistic effect,increase the curative effect,reduce blood sugar,improve renal function,and be worthy of clinical application and discussion.